TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07310784: A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma

Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 92 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,411,400

Rescue Site Savings

+$7,530,600

Unlock Full NCT07310784 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07310784 Rescue Dossier →